DXCM
DexCom, Inc.
61.57
8 x 61.50
8 x 61.62
bid
ask
-
1.13
1.80%
8 @ 04:00 PM
61.60 +0.03 (0.05%)
| Ytd | -7.23% | |
| 1y | -13.01% |
60.34
day range
62.90
54.84
52 week range
89.53
| Open | 62.68 | Prev Close | 62.70 | Low | 60.34 | High | 62.90 | Mkt Cap | 23.76B |
| Vol | 3.52M | Avg Vol | 4.51M | EPS | 2.05 | P/E | 30.03 | Forward P/E | 20.97 |
| Beta | 1.56 | Short Ratio | 3.77 | Inst. Own | 101.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 67.01 | 200-d Avg | 70.23 | 1yr Est | 86.88 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-04-30 | 2026-03 | 0.47 | N/A | N/A | N/A |
| 2026-02-12 | 2025-12 | 0.65 | 0.68 | 0.03 | 4.62% |
| 2025-10-30 | 2025-09 | 0.57 | 0.61 | 0.04 | 7.02% |
| 2025-07-30 | 2025-06 | 0.45 | 0.48 | 0.03 | 6.67% |
| 2025-05-01 | 2025-03 | 0.33 | 0.32 | -0.01 | -3.03% |
| 2025-02-13 | 2024-12 | 0.5 | 0.45 | -0.05 | -10.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-03-11 | Citigroup | Upgrade | Buy | Buy |
| 2026-03-09 | BTIG | Upgrade | Buy | Buy |
| 2026-02-25 | BTIG | Upgrade | Buy | Buy |
| 2026-02-17 | Truist Securities | Upgrade | Buy | Buy |
| 2026-02-13 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-02-13 | Barclays | Upgrade | Underweight | Underweight |
Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-05-07 | ALTMAN STEVEN R | Director | 63.67K | Stock Award(Grant) |
| 2026-04-14 | BROWN MICHAEL JON | Officer | 111.20K | Sale |
| 2026-03-05 | COLEMAN JON | Officer | 112.64K | Stock Award(Grant) |
| 2025-01-28 | DOLAN MATTHEW VINCENT | Officer | 42.04K | Sale |
| 2025-08-14 | FOLETTA MARK G | Director | 0.00 | Sale |
| 2026-03-05 | LEACH JACOB STEVEN | Chief Executive Officer | 469.11K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Vanguard Group Inc | 49.07M | 3.02B | 12.72% |
| 2025-12-30 | Blackrock Inc. | 39.85M | 2.45B | 10.33% |
| 2025-12-30 | State Street Corporation | 18.09M | 1.11B | 4.69% |
| 2025-12-30 | BAILLIE GIFFORD & CO | 15.55M | 957.57M | 4.03% |
| 2025-12-30 | Geode Capital Management, LLC | 11.01M | 677.65M | 2.85% |
| 2025-12-30 | Alliancebernstein L.P. | 8.62M | 530.99M | 2.23% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 12.26M | 755.10M | 3.18% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 9.83M | 605.43M | 2.55% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 8.49M | 522.66M | 2.20% |
| 2026-02-27 | Invesco QQQ Trust, Series 1 | 8.29M | 510.32M | 2.15% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Growth Index Fund | 5.12M | 315.20M | 1.33% |
| 2026-02-27 | Fidelity Concord Street Trust-Fidelity 500 Index Fund | 4.96M | 305.60M | 1.29% |
Split
| Split | Date |
|---|---|
| 4 : 1 | 2022-06-13 |
| 4 : 1 | 2022-06-10 |
